Insider: Patel Chintu Co-CEO - Amneal Pharmaceuticals, Inc.
| Company Holdings |
| Direct | Indirect Ownership | Total | |
| Shares | 512,566 | 0 | 512,566 |
| Value | $4,979,578.69 | $0.00 | $4,979,578.69 |
Trans. Date |
Trans. Type |
Shares |
Ownership Type |
Issue Type |
Price |
Trans. Value |
Total Shares Owned |
|---|---|---|---|---|---|---|---|
| 12/16/2021 | AAP | 50,000 | Direct | COM | $4.25 | $212,500.00 | 512,566 |
| 12/15/2021 | AAP | 100,000 | Direct | COM | $4.13 | $413,000.00 | 462,566 |
| 03/10/2020 | AAP | 100,000 | Direct | COM | $3.09 | $309,000.00 | 356,107 |
| 03/04/2020 | AAP | 58,765 | Direct | COM | $3.97 | $233,297.05 | 256,107 |
| 03/03/2020 | AAP | 156,539 | Direct | COM | $3.88 | $607,371.32 | 197,342 |
| 03/02/2020 | AAP | 34,696 | Direct | COM | $3.87 | $134,273.52 | 40,803 |
| 1 You are at page 1 of 1 pages |
|
Transaction Type Key First letter: A = Acquired, D = Disposed Second letter: A = Grant, award or other acquisition pursuant to Rule 16b-3(d) C = Conversion of derivative security | D = Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | E = Expiration of short derivative position | F = Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. | G = Gift | H = Expiration (or cancellation) of long derivative position with value received | I = Discretionary transaction in accordance with Rule 16b-3(f) | J = Other | L = Small acquisition under Rule 16a-6 | M = Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | O = Exercise of out-of-the-money derivative security | P = Open market or private purchase | S = Open market or private sale | U = Disposition pursuant to a tender of shares in a change of control transaction | W = Acquisition or disposition by will or the laws of descent and distribution | X = Exercise of in-the-money or at-the-money derivative security | Z = Deposit into or withdrawal from voting trust |
 |
Send to Excel |
© 2000 - 2025 Zacks Investment Research